酮康唑在多西他赛难治性前列腺癌患者中仍保持活性。 - Suppr

Suppr

超能文献

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

作者信息

Galsky M D, Simon K, Sonpavde G, Hutson T E, Fleming M, Kondagunta G V, Berry W

出版信息

Ann Oncol. 2009 May;20(5):965-6. doi: 10.1093/annonc/mdp199.

DOI:10.1093/annonc/mdp199

PMID:19403937

Abstract

摘要

相似文献

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

Ann Oncol. 2009 May;20(5):965-6. doi: 10.1093/annonc/mdp199.

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

Ann Oncol. 2009 May;20(5):965. doi: 10.1093/annonc/mdp112.

Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11].

Urol Oncol. 2016 May;34(5):247. doi: 10.1016/j.urolonc.2015.02.008. Epub 2015 Apr 20.

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.

Cancer. 2008 Feb 1;112(3):521-6. doi: 10.1002/cncr.23195.

Poor survival in prostate cancer patients with primary refractoriness to docetaxel.

Eur Urol. 2014 Feb;65(2):505-7. doi: 10.1016/j.eururo.2013.10.037. Epub 2013 Nov 6.

Docetaxel as a vital option for corticosteroid-refractory prostate cancer.

Int Urol Nephrol. 2011 Dec;43(4):1081-7. doi: 10.1007/s11255-011-9922-0. Epub 2011 Mar 11.

[Castration resistant prostate cancer 2011].

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24.

Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.

Urology. 2008 Jun;71(6):1181-5. doi: 10.1016/j.urology.2008.02.048. Epub 2008 Apr 9.

A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.

J Urol. 2011 Sep;186(3):882-7. doi: 10.1016/j.juro.2011.04.087. Epub 2011 Jul 24.

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs.

Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188481. doi: 10.1016/j.bbcan.2020.188481. Epub 2020 Nov 17.

引用本文的文献

Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):144-8. doi: 10.1038/pcan.2015.2. Epub 2015 Feb 10.

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May 17.

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

J Hematol Oncol. 2011 Apr 23;4:18. doi: 10.1186/1756-8722-4-18.

Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Clin Exp Metastasis. 2010;27(1):19-23. doi: 10.1007/s10585-009-9298-z. Epub 2009 Nov 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验